# Unicar-Therapy

Source: https://onco.cc/companies/unicar-therapy/  
OnCo record `unicar-therapy` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Unicar-Therapy is a China-based cell therapy company that leads 2 cancer trials in OnCo, testing the CAR-T products U16 and U32 in non-Hodgkin lymphoma and acute myeloid leukaemia.

## Summary

Unicar-Therapy is a Shanghai CAR-T developer founded in 2015 that builds its own cell therapy products on in-house platforms with integrated manufacturing. Its registered pipeline covers blood cancers and solid tumours. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT05768529 (phase 1/2, Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma) and NCT07036250 (phase 1/2, Clinical Study of U32 in Patients With Acute Myeloid Leukemia). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Shanghai Unicar-Therapy Bio-medicine Technology; 优卡迪
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: cell-therapy
- Website: http://www.unicar-therapy.com

## Sources

- Official website: http://www.unicar-therapy.com
- ClinicalTrials.gov: trials led by Unicar-Therapy: https://clinicaltrials.gov/search?lead=Shanghai%20Unicar-Therapy%20Bio-medicine%20Technology%20Co.%2CLtd

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- trials: [Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma](https://onco.cc/trials/nct05768529/), [Clinical Study of U32 in Patients With Acute Myeloid Leukemia](https://onco.cc/trials/nct07036250/)

---
JSON: https://onco.cc/api/v1/entities/unicar-therapy.json